Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...

Guggenheim maintained a Buy rating on Merck (NYSE:MRK) shares but reduced the price target to $115 from $122. The adjustment follows a comprehensive review of the pharmaceutical giant's fourth-quarter ...

Stamford, Connecticut-based SpringWorks' Gomekli (mirdametinib) has become the first medicine approved for both adults and children with plexiform neurofibromas (PN) in patients with the genetic ...

(Corrects third to last paragraph to say "the erosion from LOEs (loss of exclusivity)", not "from LOEs (levels of evidence)") ...

Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...

Analysts have had mixed feelings about Merck in recent years, with concerns the company, like other big pharmaceuticals, ...

As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease ...

Shares of Merck are sliding in early trading after ... due partly to a pause in shipments of one of its top-selling products to China Shares of Merck slid Tuesday after the drugmaker surprised ...

Executives pulled back on a 2030 sales target of $11 billion as demand for the HPV shot shrinks amid China market turmoil.

Merck, the giant pharmaceutical company with multiple facilities in eastern Pennsylvania and New Jersey, isn’t too enthused about its prospects in 2025.

We recently published a list of Jim Cramer Discussed These 12 Stocks Recently. In this article, we are going to take a look at where Merck & Co., Inc.

As Moderna maps out a more cautious future amid lower-than-expected sales of its current products, the company is bolstering ...